

Varespladib

Catalog No: tcsc1018



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

172732-68-2

Formula:

$C_{21}H_{20}N_2O_5$

Pathway:

Metabolic Enzyme/Protease

Target:

Phospholipase

Purity / Grade:

>98%

Solubility:

H₂O :

Alternative Names:

LY315920

Observed Molecular Weight:

380.39

Product Description


LY315920 (Varespladib) is a potent and selective human non-pancreatic secretory phospholipase A2 (sPLA2) inhibitor with IC₅₀ of 7 nM.

IC₅₀ value: 7 nM

Target: sPLA2

in vitro: LY315920 exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC₅₀ of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively. [2] In BAL cells challenged with human sPLA2, LY315920 at doses ranging from 0.1 μ M–3 μ M reduces the formation of thromboxane mediated by human sPLA2 in a concentration-dependent manner with an IC₅₀ of approximately 0.8 μ M. [2] In human conjunctival epithelial cell line (HCjE), LY315920 (10 μ M) significantly inhibits all-trans-retinoic acid (RA) -induced membrane-associated mucin MUC16 expression by 100% at 24 hours and 99% at 48 hours. [3]

in vivo: Ex vivo, LY315920 at doses ranging from 3 mg/kg to 30 mg/kg via i.v. inhibits human sPLA2-induced release of thromboxane from guinea pig BAL cells with ED₅₀ of 16.1 mg/kg. [2] In Transgenic Mice Expressing Human sPLA2, both oral and i.v. administration of LY315920 (0.3 mg/kg–3 mg/kg) abolishes serum sPLA2 activity in a dose and time dependent manner. [2]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!